Crystalline Form A Stability and Reproducibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing amorphous form of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide has limitations in stability, pharmacokinetic parameters, and process reproducibility, necessitating the development of a more stable and effective crystalline form for treating bromodomain-containing protein-mediated disorders.
Innovation Solution
A novel crystalline Form A of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, including its monohydrate form, is developed, characterized by improved relative humidity stability, favorable pharmacokinetic parameters, and enhanced process reproducibility, which is achieved through specific synthesis methods involving seeding and solvent mixtures like ethanol/water.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the amorphous form of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide is used, then therapeutic benefits are achieved, but stability and process reproducibility are limited
Solution Approach 1:
The patent applies parameter changes by transitioning from the amorphous form to the crystalline Form A, which fundamentally changes the physical state and molecular arrangement of the compound. This phase transition from amorphous to crystalline structure improves stability and process reproducibility while maintaining therapeutic efficacy, directly resolving the technical contradiction between reliability and ease of manufacture
Solution Approach 2:
The invention utilizes phase transitions by deliberately forming the crystalline Form A from the amorphous precursor. The patent describes the development of crystalline Form A with specific XRPD patterns, indicating a controlled phase transition that enhances material stability and manufacturing consistency, thereby resolving the contradiction between reliability and ease of manufacture
2Reliability
If the amorphous form is used, then therapeutic benefits are achieved, but pharmacokinetic parameters are not optimized
Solution Approach 1:
The patent applies parameter changes by transitioning from the amorphous form to the crystalline Form A, which fundamentally changes the physical state and molecular arrangement of the compound. This phase transition from amorphous to crystalline structure improves stability and process reproducibility while maintaining therapeutic efficacy, directly resolving the technical contradiction between reliability and ease of manufacture
Solution Approach 2:
The invention utilizes phase transitions by deliberately forming the crystalline Form A from the amorphous precursor. The patent describes the development of crystalline Form A with specific XRPD patterns, indicating a controlled phase transition that enhances material stability and manufacturing consistency, thereby resolving the contradiction between reliability and ease of manufacture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline Form A exhibits improved stability over a broad relative humidity range, maintains consistent water content, and demonstrates favorable pharmacokinetic profiles in preclinical studies, offering enhanced therapeutic efficacy and manufacturing reliability compared to the amorphous form.
Implementation Method 1
Crystalline Form A exhibits improved stability over a broad relative humidity range, maintains consistent water content
Implementation Method 2
a novel hydrated (e.g., monohydrate) crystalline Form A of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1- methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.